Research Group Metabolism (META)

Head: Dr. Rui Wang-Sattler

The META research group is studying metabolic diseases (e.g. type 2 diabetes and cardiovascular diseases). We use statistical, bioinformatical and machine learning approaches to integrate metabolomics, transcriptomics, epigenomics, genomics data, and information from public databases to better understand the pathophysiological mechanisms. This helps us to identify candidate biomarkers and drug targets, with the final goal to translate our discoveries into clinical practice.

Objectives and current projects:

  1. Identification of early candidate biomarkers of metabolic diseases
    •    Type 2 diabetes
    •    Cardiovascular diseases
    •    Schizophrenia
  2. Identification of novel pharmaceutical drug targets for cardiovascular disease
  3. Integration of OMICs data to study metabolic disease in hyperglycemia
  4. Translation of novel biomarkers into clinical practice.

Key funding:

  • OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE)
  • EU FP7: Identification and validation of novel pharmaceutical drug targets for cardiovascular disease (CarTarDis)
  • DGUV: Shift work on nurse health
  • BBMRI-LPC: Biomarkers of ischemic stroke in prospective cohorts (BiStroke),
  • EIT Health: Development of a new diagnostic tool for early detection of Type 2 Diabetes (DeTecT2D)


We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.